



This information is current as of February 22, 2019.

Reference: CD Antigens 2002

David Mason, Pascale André, Armand Bensussan, Chris Buckley, Curt Civin, Edward Clark, Masja de Haas, Sanna Goyert, Martin Hadam, Derek Hart, Václav Horejsí, Stefan Meuer, James Morrissey, Reinhard Schwartz-Albiez, Stephen Shaw, David Simmons, Mariagrazia Ugucconi, Ellen van der Schoot, Eric Vivier and Heddy Zola

J Immunol 2002; 168:2083-2086; ;
doi: 10.4049/jimmunol.168.5.2083
<http://www.jimmunol.org/content/168/5/2083>

References This article **cites 1 articles**, 0 of which you can access for free at:
<http://www.jimmunol.org/content/168/5/2083.full#ref-list-1>

Why *The JI*? Submit online.

- **Rapid Reviews! 30 days*** from submission to initial decision
- **No Triage!** Every submission reviewed by practicing scientists
- **Fast Publication!** 4 weeks from acceptance to publication

**average*

Subscription Information about subscribing to *The Journal of Immunology* is online at:
<http://jimmunol.org/subscription>

Permissions Submit copyright permission requests at:
<http://www.aai.org/About/Publications/JI/copyright.html>

Email Alerts Receive free email-alerts when new articles cite this article. Sign up at:
<http://jimmunol.org/alerts>



CD Antigens 2002¹

David Mason,² Pascale André, Armand Bensussan, Chris Buckley, Curt Civin, Edward Clark, Masja de Haas, Sanna Goyert, Martin Hadam, Derek Hart, Václav Hořejší, Stefan Meuer, James Morrissey, Reinhard Schwartz-Albiez, Stephen Shaw, David Simmons, Mariagrazia Ugucioni, Ellen van der Schoot, Eric Vivier, and Heddy Zola

The Proceedings of the 7th Human Leukocyte Differentiation Antigen (HLDA) Workshop are about to be published, detailing more than 80 new CD specificities. The next Workshop, planned for 2004, will continue this process, and a number of candidate CD molecules in the literature, identified by antibody production or gene cloning, are listed in this update.

The tradition of HLDA Workshops

The process of categorizing the antigenic molecules and epitopes associated with human white cells, via the collaborative study of monoclonal antibodies, dates back to the early 1980s, when the first HLDA Workshop was held in Paris, France. This initial meeting listed only fifteen agreed molecular entities, but it created an internationally agreed basis for the nomenclature of leukocyte molecules (the CD scheme), and also provided a forum for reporting studies on their function and practical relevance. A further six HLDA meetings have been held since the first Paris meeting. The most recent of these ("HLDA7") took place in Harrogate, U.K., and the proceedings of the meeting will be published this year (*Leucocyte Typing VII*, Oxford University Press).

The aims and approaches of the 7th HLDA Workshop

The limitations of "blind" antibody screening

It was apparent at the previous meeting, HLDA6, held in Kobe, Japan, in 1996, that the technique of detecting molecular entities by screening coded panels of monoclonal antibodies against human cells was becoming obsolete. Antibodies to the most immunogenic molecules had already been produced, and fewer laboratories than in the early days were prepared to devote resources to raising new antibodies, since the probability of finding novel reagents becomes ever less likely. In consequence, many antibodies in the 6th Workshop were reagents (submitted by laboratories that were not equipped to characterize them) which proved to be of known specificity.

Received for publication June 27, 2001. Accepted for publication January 10, 2002.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ By permission of Oxford University Press.

² Address correspondence and reprint requests to Prof. David Y. Mason, Nuffield Department of Clinical Laboratory Sciences, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, U.K. E-mail address: david.mason@ndcls.ox.ac.uk

Selection of antibodies

With these considerations in mind the 7th Workshop adopted a different approach; instead of screening poorly characterized antibodies, reagents were selected (and actively solicited) for which at least some molecular data were already available. A substantial number of monoclonal antibodies reactive with leukocyte-associated molecules exist that do not meet the traditional criterion for establishing a new CD specificity (i.e., the existence of at least two independent antibodies of the same specificity). This rule dates from the first HLDA Workshop two decades ago; since that time, biochemical and molecular biological techniques for characterizing the targets of new antibodies have come to be widely used. In consequence, it is now considered appropriate to establish a CD designation for a molecule if its gene has been cloned and at least one specific monoclonal antibody has been studied in the Workshop.

New Workshop sections

Four new sections were introduced in the 7th HLDA Workshop to add to the traditional list from past meetings: namely Dendritic Cells, Stem/Progenitor Cells, Erythroid Cells, and Carbohydrate Structures. Although it has been recognized for many years that monoclonal antibodies reactive with human leukocytes can be specific for carbohydrate epitopes (e.g., the carbohydrate CD category CD15 was identified at the first Workshop), they had not received specific attention in any Workshop. The inclusion of erythroid molecules, although it may seem out of place in a "Leukocyte Workshop," was justified by the number of molecules shared between white and red cells (e.g., cytokine receptors) that hint at unexplored functions of red cells.

The yield of new CD specificities in the 7th HLDA Workshop

This more active approach to the identification of new CD specificities represented a break with tradition, but the results justified the new approach, since a total of well over 80 new entities were added to the list of CD specificities. This compares favorably with previous Workshops (an average of less than 30 CD specificities per Workshop), and it also largely avoided the laborious screening in multiple laboratories of antibodies that prove to be directed against known CD molecules.

Tables I and II list the new specificities established at the 7th Workshop. Full details will be found in *Leucocyte Typing VII*, and

Table I. *New CD designations*

CD Designation	Name	Section	Locus Link
CD15u	Sulphated CD15	Carbohydrate structures	
CD60a	GD3	Carbohydrate structures	
CD60b	9- <i>O</i> -acetyl-GD3	Carbohydrate structures	
CD60c	7- <i>O</i> -acetyl-GD3	Carbohydrate structures	
CD75	Lactosamines	Carbohydrate structures	
CD75s	α -2,6-sialylated lactosamines (formerly CDw75 and CDw76)	Carbohydrate structures	
CD85	ILT/LIR family (see Table II)	Dendritic cells	
CD110	MPL, TPO R	Platelets	4352
CD111	PRR1/Nectin1	Myeloid cells	5818
CD112	PRR2	Myeloid cells	5819
CD133	AC133	Stem/progenitor cells	8842
CD156b	TACE/ADAM17	Adhesion structures	6868
CD158	KIR family (see Table II)	NK cells	
CD159a	NKG2A	NK cells	3821
CD160	BY55	T cells	11126
CD162R	PEN5	NK cells	6404
CD167a	Discoidin domain R (DDR1)	Adhesion structures	780
CD168	RHAMM	Adhesion structures	3161
CD169	Sialoadhesin	Adhesion structures	6614
CD170	Siglec-5	Adhesion structures	8778
CD171	L1	Adhesion structures	3897
CD172a	SIRP α	Adhesion structures	8194
CD173	Blood group H type 2	Carbohydrate structures	
CD174	Lewis y	Carbohydrate structures	
CD175	Tn	Carbohydrate structures	
CD175s	Sialyl-Tn	Carbohydrate structures	
CD176	TF	Carbohydrate structures	
CD177	NB1	Myeloid cells	
CD178	Fas ligand	Cytokine/chemokine receptors	356
CD179a	Vpre-B	B cells	7441
CD179b	λ 5	B cells	3543
CD180	RP105	B cells	4064
CD183	CXCR3	Cytokine/chemokine receptors	2833
CD184	CXCR4	Cytokine/chemokine receptors	7852
CD195	CCR5	Cytokine/chemokine receptors	1234
CDw197	CCR7	Cytokine/chemokine receptors	1236
CD200	OX2	Nonlineage molecules	4345
CD201	EPC R	Endothelial cells	10544
CD202b	Tie2 (Tek)	Endothelial cells	7010
CD203c	NPP3/PDNP3	Myeloid cells	5169
CD204	Macrophage scavenger R	Myeloid cells	4481
CD205	DEC205	Dendritic cells	4065
CD206	Macrophage mannose R	Dendritic cells	4360
CD207	Langerin	Dendritic cells	50489
CD208	DC-LAMP	Dendritic cells	
CD209	DC-SIGN	Dendritic cells	30385
CDw210	IL-10R	Cytokine/chemokine receptors	3587;3588
CD212	IL-12R	Cytokine/chemokine receptors	3594
CD213a1	IL-13R α 1	Cytokine/chemokine receptors	3597
CD213a2	IL-13R α 2	Cytokine/chemokine receptors	3598
CDw217	IL-17R	Cytokine/chemokine receptors	23765
CD220	Insulin R	Nonlineage molecules	3643
CD221	IGF1 R	Nonlineage molecules	3480
CD222	Mannose-6-phosphate/IGF2 R	Nonlineage molecules	3482
CD223	LAG-3	Nonlineage molecules	3902
CD224	γ -glutamyl transferase	Nonlineage molecules	2678
CD225	Leu13	Nonlineage molecules	8519
CD226	DNAM-1 (PTA1)	T cells	10666
CD227	MUC.1	Nonlineage molecules	4582
CD228	Melanotransferrin	Nonlineage molecules	4241
CD229	Ly9	Nonlineage molecules	4063
CD230	Prion protein	Nonlineage molecules	5621
CD231	TALLA-1/A15	Nonlineage molecules	7102
CD232	VESP R	Nonlineage molecules	10154
CD233	Band 3	Erythroid cells	6521
CD234	Fy-glycoprotein (DARC)	Erythroid cells	2532
CD235a	Glycophorin A	Erythroid cells	2993
CD235b	Glycophorin B	Erythroid cells	2994
CD235ab	Glycophorin A/B crossreactive mAbs	Erythroid cells	
CD236	Glycophorin C/D	Erythroid cells	
CD236R	Glycophorin C	Erythroid cells	2995
CD238	Kell	Erythroid cells	3792
CD239	B-CAM	Erythroid cells	4059
CD240CE	Rh30CE	Erythroid cells	6006
CD240D	Rh30D	Erythroid cells	6007
CD240DCE	Rh30D/CE crossreactive mAbs	Erythroid cells	
CD241	RhAg	Erythroid cells	6005
CD242	ICAM-4	Erythroid cells	3386
CD243	MDR-1	Stem/progenitor cells	
CD244	2B4	NK cells	51744
CD245	p220/240	T cells	
CD246	Anaplastic lymphoma kinase	T cells	238
CD247	ζ -chain	T cells	919

Table II. *New CD nomenclature for ILT/LIR and KIR molecules^a*

CD Designation	Name
The ILT/LIR family	
CD85a	ILT5/LIR3
CD85b	ILT8
CD85c	LIR8
CD85d	ILT4/LIR2, MIR10
CD85e	ILT6/LIR4
CD85f	ILT11
CD85g	ILT7
CD85h	ILT1/LIR7
CD85i	LIR6
CD85j	ILT2/LIR1, MIR7
CD85k	ILT3/LIR5
CD85l	ILT9
CD85m	ILT10
The KIR family	
CD158z	KIR3DL7/KIRC1
CD158b1 and CD158b2	KIR2DL2/p58.2 and KIR2DL3/p58.3
CD158a	KIR2DL1/p58.1
CD158c	KIR2DS6/KIRX
CD158d	KIR2DL4
CD158e1 and CD158e2	KIR3DL1/p70 and KIR3DS1/p70
CD158f	KIR2DL5
CD158g	KIR2DS5
CD158h	KIR2DS1/p50.1
CD158i	KIR2DS4/p50.3
CD158j	KIR2DS2/p50.2
CD158k	KIR3DL2/p140

^a For further details of this classification, based on the position of the genes on chromosome 19q13.4 from centromeric to telomeric loci, see Ref. 1.

molecular, functional, and other data can be found for many of these new specificities on the Protein Reviews on the Web (PROW) Web site (<http://www.ncbi.nlm.nih.gov/prow/>).

The 8th Workshop

Plans are well advanced for the 8th Workshop (see www.hlda8.org), to be organized in Adelaide, Australia, in 2004 under the aegis of Prof. H. Zola (Child Health Research Institute, Adelaide, Australia). It is sometimes assumed that the catalog of surface molecules associated with human hemopoietic cells is now essentially complete, but there is abundant evidence in the literature for novel surface molecules that would merit study at the next Workshop, and that could provide the basis for new CD designations. Table III comprises a list of potential new molecules reported following the production of monoclonal antibodies, and also a more extensive list of surface molecules identified via gene cloning. In most instances, no antibodies are available against the putative new leukocyte/endothelial markers in this latter group. Specific and well characterized reagents, whether monoclonal or polyclonal, are needed not only for detecting these new "virtual" molecules but also for defining functional domains, for characterizing three-dimensional protein structure, and for analyzing protein-protein interactions. It may be added that cloning of gene sequences often reveals multiple members of new or existing molecular families (e.g., the Toll-like receptors) and may identify surface receptors that bind more than one ligand or vice versa, (e.g., the TALL-1 and APRIL ligands for TAC1 and BCMA). Furthermore, a number of leukocyte-associated markers have been cloned from mice and other species, and almost all will have human homologues. The 8th Workshop will provide a forum for a

Table III. *Examples of possible future CD specificities*

Molecule	Molecule Size	Cell Types	Comments	Refs.
Identified following antibody production				
AM-3K antigen	70 and 120 kDa	Macrophages		Zeng L. et al., <i>J. Pathol.</i> 1996; 178:207.
BDCA-2, BDCA-3, and BDCA-4 antigens		Dendritic cells	Identifies subsets of dendritic cells	Dzionic A. et al., <i>J. Immunol.</i> 2000; 165:6037.
BENE	17 kDa	Endothelium	"Raft-associated" member of MAL family; interacts with caveolin-1	de Marco et al., <i>J. Biol. Chem.</i> 2001; 276:23009.
CMRF-44	?	Dendritic cells	Differentiated/activated	Hock B. D. et al., <i>Immunology</i> 1994; 83:573.
CMRF-56	95 kDa	Dendritic cells	Differentiated/activated	Hock B. D. et al., <i>Tissue Antigens</i> 1999; 53:320.
H47 antigen	100 kDa (non red.) 120 kDa (red.)	T cells and most NK, B cells and monocytes	? Involved in T cell activation	Hirohashi N. et al., <i>Cell Immunol.</i> 1993; 152:371.
Hal-1	200 kDa (100 kDa)	T cells, EBV-transformed B-cells, myelomonocytic cells, anaplastic large cell lymphoma	? New lymphoma marker	Asanuma H. et al., <i>Br. J. Haematol.</i> 1999; 106:55.
LAK1 and LAK2 antigens	120 kDa and 110 + 140 kDa respectively	LGL and LAK cells		Zocchi M. R. et al., <i>Cell Immunol.</i> 1989; 124:144.
NKp80	80 kDa dimer	NK cells and CD56-positive T cells	Novel member of the killer cell lectin-like receptor gene family, encoded by KLRF1 gene; triggers NK cell cytotoxicity	Vitale M. et al., <i>Eur. J. Immunol.</i> 2001; 31:233.
VAP-1 (vascular adhesion protein)	90 kDa	Endothelium	Mediates lymphocyte-endothelial adhesion; has monoamine oxidase activity	Roda-Navarro P. et al., <i>Eur. J. Immunol.</i> 2000; 30:568.
Wue-1 antigen	94 kDa	Plasma cells	Stimulates growth of plasma cells	Bono P. et al., <i>J. Immunol.</i> 1998; 160:5563.
				Salmi M. and Jalkanen S. <i>Science</i> 1992; 257:1407.
				Greiner A. et al., <i>Virchows Arch.</i> 2000; 437:372.

(Table continues)

Table III. *Continued*

Molecule	Molecule Size	Cell Types	Comments	Refs.
Identified via gene cloning B cell maturation factor (BCMA)	184 aa	B cells	TNFR family member; receptor for TALL-1 and APRIL	Madry et al., <i>Int. Immunol.</i> 1998; 10:1693. Shu H. B. and Johnson H., <i>Proc. Natl. Acad. Sci. USA</i> 2000; 97:9156.
B7-H2	302 aa	Dendritic cells	New member of B7 family; binds ICOS on activated T cells	Wang S. et al., <i>Blood</i> 2000; 96:2808.
CLEC-1	280 aa	Dendritic cells	Novel C-type lectin-like receptor with cytoplasmic tyrosine-based motif	Colonna M. et al., <i>Eur.</i> <i>J. Immunol.</i> 2000; 30:697.
CMRF-35A	224 aa	NK cells, neutrophils, monocytes, dendritic cells and subset of T lymphocytes	Novel Ig superfamily receptors. CMRF-35H contains 3 cytoplasmic tyrosine based motifs	Jackson et al., <i>Eur. J.</i> <i>Immunol.</i> 1992; 22:1157.
CMRF-35H	300 aa			Green et al., <i>Int. Immunol.</i> 1998; 10:891.
CS1		NK cells	Novel receptor belonging to CD2 subset of Ig superfamily	Boles K. S. et al., <i>Immunogenetics</i> 2001; 52: 302.
DC-STAMP	470 aa	Dendritic cells	Novel protein containing seven putative transmembrane domains.	Hartgers F. C. et al., <i>Eur.</i> <i>J. Immunol.</i> 2000; 30:3585.
EMR3	652 aa	Mainly leukocyte restricted; highest levels on neutrophils, monocytes and macrophages	Novel EGF-TM7 molecule. Interacts with a surface ligand on myeloid cells.	Stacey M. et al., <i>J. Biol.</i> <i>Chem.</i> 2001; 276:18863.
Flt-1 (VEGFR-1)		Endothelial cells, monocytes		Sawano A. et al., <i>Blood</i> 2001; 97:785.
GPRv53	390 aa	Leukocytes	Identified by gene cloning; G- protein-coupled histamine receptor	Oda T. et al., <i>J. Biol. Chem.</i> 2000; 275:36781.
IRTA1 and IRTA2		Subpopulations of B cells	Homologous to the Fc and inhibitory receptor families	Hatzivassiliou G. et al., <i>Immunity</i> 2001; 14:277.
M160	1453 aa	Macrophages	New member of scavenger receptor cysteine-rich superfamily	Gronlund J. et al., <i>J. Immunol.</i> 2000; 165:6406.
MARCO (macrophage receptor with collagenous structure)	520 aa	Macrophages	Class A scavenger receptor; involved in bacterial clearance in vivo	Elomaa et al., <i>J. Biol. Chem.</i> 1998; 273:4530. Van der Laan L. J. et al., <i>J. Immunol.</i> 1999; 162:939.
TAC1	293 aa	B cells	TNFR family member. Receptor for TALL-1 and APRIL	Xia X. Z. et al., <i>J. Exp. Med.</i> 2000; 192:137.
TREM-1 and TREM-2 (triggering receptors expressed on myeloid cells)		Neutrophils and subset of monocytes (TREM-1) and macrophages (TREM-2)	Novel Ig superfamily receptors. TREM-1 triggers neutrophil secretion (e.g. IL-8) and degranulation; TREM-2 activates macrophages; both associate with DAP12.	Bouchon A. et al., <i>J. Immunol.</i> 2000; 164:4991. Daws M. R. et al., <i>Eur.</i> <i>J. Immunol.</i> 2001; 31:783.

range of antibody-based studies relating to this accumulating corpus of genomic and proteomic data.

As in the 7th Workshop in which four new sections were added, it may be possible to include neuronal cells in the 8th Workshop. Many neuronal cells express cell surface proteins found on leukocytes and vice versa (e.g., CD56, CD100, CD168, and CD171). Furthermore, the guidance cues used by neuronal cells share similarities to those involved in leukocyte extravasation so the expression of these molecules in common may reflect shared biological processes. It may also be noted that other molecules such as the mucins thought to be primarily associated with epithelial cells, are now being described on leukocytes.

Finally, it remains to be established how the 8th and subsequent HLDA Workshops should deal with lineage- or stage-restricted

leukocyte molecules that are localized within the cell cytoplasm (or nucleus). Given the importance of many of these molecules in signaling pathways initiated via known surface CD molecules, their identification and study is an inevitable extension of the work of the first seven HLDA Workshops. Whether or not a new "intracellular CD" categorization scheme is devised for such molecules, they are of interest for many laboratories interested in human hematopoietic cells, and their study will be among the aims of the next Workshop.

Reference

- André, P., R. Biassoni, M. Colonna, D. Cosman, L. L. Lanier, E. O. Long, M. Lopez-Botet, A. Moretta, L. Moretta, P. Parham, et al. 2001. New nomenclature for MHC receptors. *Nat. Immunol.* 2:661.